- Home
- DSGN vs HTCO Comparison
DSGN vs HTCO Comparison
Compare DSGN & HTCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- HTCO
- Stock Information
- Founded
- DSGN 2017
- HTCO N/A
- Country
- DSGN United States
- HTCO Singapore
- Employees
- DSGN N/A
- HTCO N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- HTCO
- Sector
- DSGN Health Care
- HTCO
- Exchange
- DSGN Nasdaq
- HTCO NYSE
- Market Cap
- DSGN 348.2M
- HTCO 360.8M
- IPO Year
- DSGN 2021
- HTCO N/A
- Fundamental
- Price
- DSGN $4.87
- HTCO $3.77
- Analyst Decision
- DSGN Hold
- HTCO
- Analyst Count
- DSGN 3
- HTCO 0
- Target Price
- DSGN $7.00
- HTCO N/A
- AVG Volume (30 Days)
- DSGN 220.6K
- HTCO 153.1K
- Earning Date
- DSGN 03-18-2025
- HTCO 01-01-0001
- Dividend Yield
- DSGN N/A
- HTCO N/A
- EPS Growth
- DSGN N/A
- HTCO N/A
- EPS
- DSGN N/A
- HTCO N/A
- Revenue
- DSGN N/A
- HTCO $80,567,672.00
- Revenue This Year
- DSGN N/A
- HTCO N/A
- Revenue Next Year
- DSGN N/A
- HTCO N/A
- P/E Ratio
- DSGN N/A
- HTCO N/A
- Revenue Growth
- DSGN N/A
- HTCO N/A
- 52 Week Low
- DSGN $2.25
- HTCO $0.21
- 52 Week High
- DSGN $7.77
- HTCO $4.50
- Technical
- Relative Strength Index (RSI)
- DSGN 42.19
- HTCO N/A
- Support Level
- DSGN $3.71
- HTCO N/A
- Resistance Level
- DSGN $6.81
- HTCO N/A
- Average True Range (ATR)
- DSGN 0.50
- HTCO 0.00
- MACD
- DSGN -0.10
- HTCO 0.00
- Stochastic Oscillator
- DSGN 37.42
- HTCO 0.00
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About HTCO CARAVELLE INTERNATIONAL GROUP
Caravelle International Group is an international operator of ocean transportation services. It is engaged in the seaborne transportation service under voyage contracts as well as vessel service for and on behalf of ship owners. The company has two operating segments namely, ocean transport and Heating business. The company derives the majority of its revenue from the Ocean transportation business. The company derives freight revenue from voyage contracts and provides vessel service.